The administration of oseltamivir results in reduced effector and memory CD8+ T cell responses to influenza and affects protective immunity

FASEB Journal

Volumn 29, Issue 3, 2015, Pages 973-987

  Marois, Isabelle ^a   Cloutier, Alexandre ^a   Garneau, Émilie ^a   Lesur, Olivier ^a   Richter, Martin V ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

Adaptive immune response; Antiviral; Flu; Immunologic consequences; Tamiflu

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; OSELTAMIVIR; RANTES; SODIUM CHLORIDE; VIRUS ANTIBODY; ANTIVIRUS AGENT; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIVIRAL ACTIVITY; ARTICLE; BODY WEIGHT; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL LINE; CELL MIGRATION; CELL STIMULATION; CELL SURFACE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HEMAGGLUTINATION INHIBITION TEST; IMMUNE RESPONSE; IMMUNITY; IMMUNOLOGICAL MEMORY; INFLUENZA; LOW DRUG DOSE; LUNG LAVAGE; LYMPH NODE; LYMPHOCYTE COUNT; MACROPHAGE; MONOCYTE; MORBIDITY; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIMARY INFECTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REINFECTION; SECONDARY INFECTION; VIRAL CLEARANCE; VIRUS LOAD; VIRUS REPLICATION; ADAPTIVE IMMUNITY; ANIMAL; BLOOD; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; GENETICS; IMMUNOLOGY; INFLUENZA A VIRUS; LUNG; ORTHOMYXOVIRIDAE INFECTIONS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIROLOGY;

MUS;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FEMALE; FLOW CYTOMETRY; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS; LUNG; LYMPH NODES; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84937411911     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.14-260687     Document Type: Article

References (61)

1. Stöhr, K. (2003) Preventing and treating influenza. BMJ 326, 1223-1224
2. Fiore, A. E., Fry, A., Shay, D., Gubareva, L., Bresee, J. S., and Uyeki, T. M.; Centers for Disease Control and Prevention (CDC). (2011) Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 60, 1-24
3. Hayden, F. G., Atmar, R. L., Schilling, M., Johnson, C., Poretz, D., Paar, D., Huson, L., Ward, P., and Mills, R. G. (1999) Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N. Engl. J. Med. 341, 1336-1343
4. Hayden, F. G., Treanor, J. J., Fritz, R. S., Lobo, M., Betts, R. F., Miller, M., Kinnersley, N., Mills, R. G., Ward, P., and Straus, S. E. (1999) Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 282, 1240-1246
5. Aoki, F. Y., Macleod, M. D., Paggiaro, P., Carewicz, O., El Sawy, A., Wat, C., Griffiths, M., Waalberg, E., and Ward, P.; IMPACT Study Group. (2003) Early administration of oral oseltamivir increases the benefits of influenza treatment. J. Antimicrob. Chemother. 51, 123-129
6. Kim, C. U., Chen, X., and Mendel, D. B. (1999) Neuraminidase inhibitors as anti-influenza virus agents. Antivir. Chem. Chemother. 10, 141-154
7. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza; Bautista, E., Chotpitayasunondh, T., Gao, Z., Harper, S. A., Shaw, M., Uyeki, T. M., Zaki, S. R., Hayden, F. G., Hui, D. S., Kettner, J. D., Kumar, A., Lim, M., Shindo, N., Penn, C., and Nicholson, K. G. (2010) Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N. Engl. J. Med. 362, 1708-1719
8. Poland, G. A., Jacobson, R. M., and Ovsyannikova, I. G. (2009) Influenza virus resistance to antiviral agents: a plea for rational use. Clin. Infect. Dis. 48, 1254-1256
9. Meijer, A., Lackenby, A., Hungnes, O., Lina, B., van-der-Werf, S., Schweiger, B., Opp, M., Paget, J., van-de-Kassteele, J., Hay, A., and Zambon, M.; European Influenza Surveillance Scheme. (2009) Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis. 15, 552-560
10. Lipsitch, M., Cohen, T., Murray, M., and Levin, B. R. (2007) Antiviral resistance and the control of pandemic influenza. PLoS Med. 4, e15
11. Peiris, J. S., Hui, K. P., and Yen, H. L. (2010) Host response to influenza virus: protection versus immunopathology. Curr. Opin. Immunol. 22, 475-481
12. Rouse, B. T., and Sehrawat, S. (2010) Immunity and immunopathology to viruses: what decides the outcome? Nat. Rev. Immunol. 10, 514-526
13. Kohlmeier, J. E., and Woodland, D. L. (2009) Immunity to respiratory viruses. Annu. Rev. Immunol. 27, 61-82
14. + T cell responses. J. Immunol. 166, 4627-4633
15. Flynn, K. J., Belz, G. T., Altman, J. D., Ahmed, R., Woodland, D. L., and Doherty, P. C. (1998) Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity 8, 683-691
16. Wiley, J. A., Hogan, R. J., Woodland, D. L., and Harmsen, A. G. (2001) Antigen-specific CD8(+) T cells persist in the upper respiratory tract following influenza virus infection. J. Immunol. 167, 3293-3299
17. Lawrence, C. W., Ream, R. M., and Braciale, T. J. (2005) Frequency, specificity, and sites of expansion of CD8+ T cells during primary pulmonary influenza virus infection. J. Immunol. 174, 5332-5340
18. + T cells persist in the lungs following recovery from respiratory virus infections. J. Immunol. 166, 1813-1822
19. Ely, K. H., Cookenham, T., Roberts, A. D., and Woodland, D. L. (2006) Memory T cell populations in the lung airways are maintained by continual recruitment. J. Immunol. 176, 537-543
20. Purwar, R., Campbell, J., Murphy, G., Richards, W. G., Clark, R. A., and Kupper, T. S. (2011) Resident memory T cells (T (RM)) are abundant in human lung: diversity, function, and antigen specificity. PLoS One 6, e16245
21. Burger, R. A., Billingsley, J. L., Huffman, J. H., Bailey, K. W., Kim, C. U., and Sidwell, R. W. (2000) Immunological effects of the orally administered neuraminidase inhibitor oseltamivir in influenza virus-infected and uninfected mice. Immunopharmacology 47, 45-52
22. Hatta, Y., Hershberger, K., Shinya, K., Proll, S. C., Dubielzig, R. R., Hatta, M., Katze, M. G., Kawaoka, Y., and Suresh, M. (2010) Viral replication rate regulates clinical outcome and CD8 T cell responses during highly pathogenic H5N1 influenza virus infection in mice. PLoS Pathog. 6, e1001139
23. Carroll, T. D., Matzinger, S. R., Genescà, M., Fritts, L., Colòn, R., McChesney, M. B., and Miller, C. J. (2008) Interferon-induced expression of MxA in the respiratory tract of rhesus macaques is suppressed by influenza virus replication. J. Immunol. 180, 2385-2395
24. Walsh, K. B., Teijaro, J. R., Wilker, P. R., Jatzek, A., Fremgen, D. M., Das, S. C., Watanabe, T., Hatta, M., Shinya, K., Suresh, M., Kawaoka, Y., Rosen, H., and Oldstone, M. B. (2011) Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc. Natl. Acad. Sci. USA 108, 12018-12023
25. Treanor, J. J., Hayden, F. G., Vrooman, P. S., Barbarash, R., Bettis, R., Riff, D., Singh, S., Kinnersley, N., Ward, P., and Mills, R. G.; US Oral Neuraminidase Study Group. (2000) Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 283, 1016-1024
26. Peters, Jr., P. H., Gravenstein, S., Norwood, P., De Bock, V., Van Couter, A., Gibbens, M., von Planta, T. A., and Ward, P. (2001) Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J. Am. Geriatr. Soc. 49, 1025-1031
27. Takahashi, E., Kataoka, K., Fujii, K., Chida, J., Mizuno, D., Fukui, M., Hiro-O Ito, Fujihashi, K., and Kido, H. (2010) Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus. Microbes Infect. 12, 778-783
28. Sawabuchi, T., Suzuki, S., Iwase, K., Ito, C., Mizuno, D., Togari, H., Watanabe, I., Talukder, S. R., Chida, J., and Kido, H. (2009) Boost of mucosal secretory immunoglobulin A response by clarithromycin in paediatric influenza. Respirology 14, 1173-1179
29. Wong, Z. X., Jones, J. E., Anderson, G. P., and Gualano, R. C. (2011) Oseltamivir treatment of mice before or after mild influenza infection reduced cellular and cytokine inflammation in the lung. Influenza Other Respir. Viruses 5, 343-350
30. Cloutier, A., Marois, I., Cloutier, D., Verreault, C., Cantin, A. M., and Richter, M. V. (2012) The prostanoid 15-deoxy-Δ12,14-prostaglandin-j2 reduces lung inflammation and protects mice against lethal influenza infection. J. Infect. Dis. 205, 621-630
31. Marois, I., Cloutier, A., Garneau, É., and Richter, M. V. (2012) Initial infectious dose dictates the innate, adaptive, and memory responses to influenza in the respiratory tract. J. Leukoc. Biol. 92, 107-121
32. Leneva, I. A., Roberts, N., Govorkova, E. A., Goloubeva, O. G., and Webster, R. G. (2000) The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res. 48, 101-115
33. Mendel, D. B., Tai, C. Y., Escarpe, P. A., Li, W., Sidwell, R. W., Huffman, J. H., Sweet, C., Jakeman, K. J., Merson, J., Lacy, S. A., Lew, W., Williams, M. A., Zhang, L., Chen, M. S., Bischofberger, N., and Kim, C. U. (1998) Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob. Agents Chemother. 42, 640-646
34. Govorkova, E. A., Ilyushina, N. A., Boltz, D. A., Douglas, A., Yilmaz, N., and Webster, R. G. (2007) Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob. Agents Chemother. 51, 1414-1424
35. Govorkova, E. A., Marathe, B. M., Prevost, A., Rehg, J. E., and Webster, R. G. (2011) Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets. Antiviral Res. 91, 81-88
36. Holt, P. G., Strickland, D. H., Wikström, M. E., and Jahnsen, F. L. (2008) Regulation of immunological homeostasis in the respiratory tract. Nat. Rev. Immunol. 8, 142-152
37. Sanders, C. J., Doherty, P. C., and Thomas, P. G. (2011) Respiratory epithelial cells in innate immunity to influenza virus infection. Cell Tissue Res. 343, 13-21
38. Kohlmeier, J. E., Reiley, W. W., Perona-Wright, G., Freeman, M. L., Yager, E. J., Connor, L. M., Brincks, E. L., Cookenham, T., Roberts, A. D., Burkum, C. E., Sell, S., Winslow, G. M., Blackman, M. A., Mohrs, M., and Woodland, D. L. (2011) Inflammatory chemokine receptors regulate CD8(+) T cell contraction and memory generation following infection. J. Exp. Med. 208, 1621-1634
39. La Gruta, N. L., Turner, S. J., and Doherty, P. C. (2004) Hierarchies in cytokine expression profiles for acute and resolving influenza virus-specific CD8+ T cell responses: correlation of cytokine profile and TCR avidity. J. Immunol. 172, 5553-5560
40. LaMere, M. W., Lam, H. T., Moquin, A., Haynes, L., Lund, F. E., Randall, T. D., and Kaminski, D. A. (2011) Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J. Immunol. 186, 4331-4339
41. Qiu, C., Huang, Y., Wang, Q., Tian, D., Zhang, W., Hu, Y., Yuan, Z., Zhang, X., and Xu, J. (2012) Boosting heterosubtypic neutralization antibodies in recipients of 2009 pandemic H1N1 influenza vaccine. Clin. Infect. Dis. 54, 17-24
42. Potter, C. W., and Oxford, J. S. (1979) Determinants of immunity to influenza infection in man. Br. Med. Bull. 35, 69-75
43. Sidwell, R. W., Huffman, J. H., Barnard, D. L., Bailey, K. W., Wong, M. H., Morrison, A., Syndergaard, T., and Kim, C. U. (1998) Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res. 37, 107-120
44. Perrone, L. A., Plowden, J. K., García-Sastre, A., Katz, J. M., and Tumpey, T. M. (2008) H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog. 4, e1000115
45. Powell, T. J., Dwyer, D. W., Morgan, T., Hollenbaugh, J. A., and Dutton, R. W. (2006) The immune system provides a strong response to even a low exposure to virus. Clin. Immunol. 119, 87-94
46. de Jong, M. D., Simmons, C. P., Thanh, T. T., Hien, V. M., Smith, G. J., Chau, T. N., Hoang, D. M., Chau, N. V., Khanh, T. H., Dong, V. C., Qui, P. T., Cam, B. V., Ha do, Q., Guan, Y., Peiris, J. S., Chinh, N. T., Hien, T. T., and Farrar, J. (2006) Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12, 1203-1207
47. Tumpey, T. M., García-Sastre, A., Taubenberger, J. K., Palese, P., Swayne, D. E., Pantin-Jackwood, M. J., Schultz-Cherry, S., Solórzano, A., Van Rooijen, N., Katz, J. M., and Basler, C. F. (2005) Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J. Virol. 79, 14933-14944
48. Ilyushina, N. A., Hay, A., Yilmaz, N., Boon, A. C., Webster, R. G., and Govorkova, E. A. (2008) Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob. Agents Chemother. 52, 3889-3897
49. Topham, D. J., Tripp, R. A., and Doherty, P. C. (1997) CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. J. Immunol. 159, 5197-5200
50. Piqueras, B., Connolly, J., Freitas, H., Palucka, A. K., and Banchereau, J. (2006) Upon viral exposure, myeloid and plasmacytoid dendritic cells produce 3 waves of distinct chemokines to recruit immune effectors. Blood 107, 2613-2618
51. Bromley, S. K., Mempel, T. R., and Luster, A. D. (2008) Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat. Immunol. 9, 970-980
52. Wherry, E. J., and Ahmed, R. (2004) Memory CD8 T-cell differentiation during viral infection. J. Virol. 78, 5535-5545
53. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus; Abdel-Ghafar, A. N., Chotpitayasunondh, T., Gao, Z., Hayden, F. G., Nguyen, D. H., de Jong, M. D., Naghdaliyev, A., Peiris, J. S., Shindo, N., Soeroso, S., and Uyeki, T. M. (2008) Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med. 358, 261-273
54. Centers for Disease Control and Prevention (CDC). (2009) Intensive-care patients with severe novel influenza A (H1N1) virus infection - Michigan, June 2009. MMWR Morb. Mortal. Wkly. Rep. 58, 749-752
55. Moore, M. L., Chi, M. H., Zhou, W., Goleniewska, K., O'Neal, J. F., Higginbotham, J. N., and Peebles, Jr., R. S. (2007) Cutting Edge: oseltamivir decreases T cell GM1 expression and inhibits clearance of respiratory syncytial virus: potential role of endogenous sialidase in antiviral immunity. J. Immunol. 178, 2651-2654
56. Gómez-Móuton, C., Abad, J. L., Mira, E., Lacalle, R. A., Gallardo, E., Jiménez-Baranda, S., Illa, I., Bernad, A., Mañes, S., and Martínez-A, C. (2001) Segregation of leading-edge and uropod components into specific lipid rafts during T cell polarization. Proc. Natl. Acad. Sci. USA 98, 9642-9647
57. Liang, S., Mozdzanowska, K., Palladino, G., and Gerhard, W. (1994) Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J. Immunol. 152, 1653-1661
58. Ray, S. J., Franki, S. N., Pierce, R. H., Dimitrova, S., Koteliansky, V., Sprague, A. G., Doherty, P. C., de Fougerolles, A. R., and Topham, D. J. (2004) The collagen binding alpha1beta1 integrin VLA-1 regulates CD8 T cell-mediated immune protection against heterologous influenza infection. Immunity 20, 167-179
59. Kohlmeier, J. E., Miller, S. C., Smith, J., Lu, B., Gerard, C., Cookenham, T., Roberts, A. D., and Woodland, D. L. (2008) The chemokine receptor CCR5 plays a key role in the early memory CD8+ T cell response to respiratory virus infections. Immunity 29, 101-113
60. Jefferson, T., Jones, M. A., Doshi, P., Del Mar, C. B., Heneghan, C. J., Hama, R., and Thompson, M. J. (2012) Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst. Rev. 1, CD008965
61. Shinahara, W., Takahashi, E., Sawabuchi, T., Arai, M., Hirotsu, N., Takasaki, Y., Shindo, S., Shibao, K., Yokoyama, T., Nishikawa, K., Mino, M., Iwaya, M., Yamashita, Y., Suzuki, S., Mizuno, D., and Kido, H. (2013) Immunomodulator clarithromycin enhances mucosal and systemic immune responses and reduces reinfection rate in pediatric patients with influenza treated with antiviral neuraminidase inhibitors: a retrospective analysis. PLoS One 8, e70060